Gastroenterology

Healthcare Weekly News and Deals

1. Hinge Health, Inc. (NYSE: HNGE) has signed a definitive agreement to acquire virtual-first digestive care provider Cylinder Health, Inc. for $105 million in cash. Hinge Health (NYSE: HNGE) is deploying $105 million of cash to enter gastrointestinal care, a category it sizes at $135 billion of annual U.S. medical spend affecting roughly one in four adults. Cylinder brings nearly 100 clients across two million lives, relationships with two of the three largest PBMs and three of the top five health plans by self-insured share, and more than 150,000 patients treated with a clinically validated ROI. The rationale is cross-sell economics: Hinge cites high comorbidity with its existing MSK and migraine populations. An integrated GI program launches in 2027; closing is expected in the third quarter of 2026. (Link)
2. KKR has agreed to acquire Integer Holdings Corporation (NYSE: ITGR), the Plano, Texas-based medical device contract development and manufacturing organization, in an all-cash take-private valuing the company at an enterprise value of approximately $5.7 billion. KKR is paying $127.00 per share in cash for Integer Holdings (NYSE: ITGR), a 51.8% premium to Integer’s April 29, 2026 close and 28.8% over its 30-day VWAP as of July 31, 2026. The deal follows a board-led strategic review launched in April and is financed with equity from KKR-managed funds plus committed debt, with no financing contingency. KKR, which reported $796 billion of assets under management at quarter end, deepens a healthcare book that already includes the 2018 Envision take-private, and plans to establish an employee ownership program at Integer. Closing is expected by year-end 2026 and Integer will delist from the NYSE. (Link)
3. Teleflex Incorporated (NYSE: TFX) has completed the divestiture of its OEM business to private equity firms Montagu and Kohlberg for $1.5 billion in cash, with the unit relaunched as Ingenyx. Montagu and Kohlberg have closed their $1.5 billion all-cash purchase of Teleflex’s (NYSE: TFX) contract manufacturing arm, carved out via Lotus US Bidco Inc. and rebranded Ingenyx. Teleflex estimates approximately $1.25 billion in after-tax proceeds and will apply them to $800 million of debt reduction and completion of a $1 billion share repurchase authorization. The sale was first announced in December 2025 alongside the Acute Care unit at $2.03 billion of combined value. For Teleflex, the exit concentrates the portfolio on Vascular Access, Interventional and Surgical; for the sponsors, it delivers a standalone medtech CDMO platform. (Link)
4. Nordic Capital has agreed to carve out BWX Technologies, Inc.’s (NYSE: BWXT) medical business, including BWXT Medical and Kinectrics’ stable medical isotopes unit, in a transaction valued at up to $800 million. Nordic Capital, which manages roughly EUR 39 billion and runs a dedicated healthcare franchise, is acquiring BWXT’s (NYSE: BWXT) radiopharmaceutical platform in a carve-out valued at up to $800 million. BWXT has roughly tripled the unit’s revenue since buying it in 2018 and will retain a meaningful minority stake, allowing it to redeploy capital toward nuclear national security and commercial nuclear power. Partner Christian Hedegaard framed radiopharmaceuticals as sitting at the intersection of Nordic’s pharmaceutical and life sciences track record. The transaction is subject to customary regulatory approvals and is expected to close by the end of 2026. (Link)
5. iRhythm Technologies, Inc. (NASD: IRTC) has agreed to acquire San Jose-based wearable biosensor company VitalConnect for $287.5 million, comprising $237.5 million in cash and approximately $50 million in iRhythm stock. iRhythm (NASDAQ: IRTC) is paying $287.5 million for VitalConnect, a private FDA-cleared biosensor platform running at an approximately $65 million annual revenue run rate, in a move that pushes iRhythm deeper into mobile cardiac telemetry. The deal was disclosed alongside 2Q26 results showing 20.1% year-over-year revenue growth and a $50 million patent settlement with Baxter. BTIG’s Marie Thibault called the deal surprising and expects mixed investor reaction, flagging concerns it could mask an MCT slowdown while noting the timing likely reflects VitalConnect’s capital needs. Management expects revenue contribution from 2027; closing is targeted by year-end. (Link)
6. Jazz Pharmaceuticals (NASD:JAZZ) to acquire Actio Biosciences for $820 million upfront plus up to $500 million in milestones Jazz Pharmaceuticals (NASDAQ: JAZZ) has agreed to acquire privately held Actio Biosciences for $820 million in cash upfront and up to $500 million in contingent payments. The deal adds ABS-1230, a clinical-stage precision therapy targeting KCNT1+ epilepsy, a rare and severe developmental epileptic encephalopathy with no FDA-approved treatments. Jazz will also take a minority stake in a new spin-out company focused on other genetic rare neurological diseases. Closing is expected in the fourth quarter of 2026. (Link)
7. Tarsus Pharmaceuticals (NASD:TARS) to acquire Alkeus Pharmaceuticals for approximately $450 million upfront plus up to $350 million in milestones Tarsus Pharmaceuticals (NASDAQ: TARS) has entered a definitive agreement to acquire Alkeus Pharmaceuticals, adding gildeuretinol (ALK-001), a Phase 3 oral investigational therapy for Stargardt disease. Consideration consists of roughly $270 million in cash and $180 million in Tarsus stock, plus up to $350 million in regulatory and commercial milestones and low single-digit royalties. The asset has Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations; Phase 3 NORTHSTAR topline data are expected in the second half of 2029. Closing is anticipated in 2026. (Link)
8. Supernus Pharmaceuticals (NASD:SUPN) and Indivior Pharmaceuticals (NASD:INDV) to merge in all-stock transaction, creating a diversified CNS company Supernus Pharmaceuticals (NASDAQ: SUPN) and Indivior Pharmaceuticals (NASDAQ: INDV) have agreed to combine in a tax-free all-stock merger of equals. The combined company, to be named Supernus, Inc., is expected to generate approximately $2.2 billion in pro forma annual revenue and $125 million in annual cost synergies. Indivior stockholders will receive a $1 billion special cash dividend immediately prior to closing and will own about 56.5% of the combined entity. Jack Khattar will serve as CEO. Closing is targeted for the fourth quarter of 2026. (Link)
9. Keensight Capital-backed Isto Biologics has acquired NovaBone Products LLC from Halma plc (LSE: HLMA) for approximately $60 million, expanding its bone graft substitutes platform. Keensight Capital, a pan-European growth buyout manager, has supported portfolio company Isto Biologics in acquiring NovaBone from Halma (LSE: HLMA) for a total consideration of roughly $60 million on a cash-free, debt-free basis. Completed just ten months after Keensight’s investment, this is Isto’s first bolt-on and the opening move in an explicit buy-and-build toward a transatlantic orthobiologics leader. Partners Amit Karna and David Piccoli cited product breadth and geographic reach as the value drivers. Alachua, Florida-based NovaBone sells bioactive glass synthetic grafts in over 40 countries across spine, orthopedic, trauma, extremities and dental applications. (Link)
10. Eir Partners Capital has made a strategic investment in ClaimsBridge, which simultaneously acquired dialysis cost-containment specialist DialysisPPO, expanding its healthcare cost management ecosystem. Eir Partners Capital, a private equity firm focused on healthcare technology and tech-enabled services, has backed Arnold, Maryland-based ClaimsBridge in a dual transaction announced August 6, 2026. Terms were undisclosed. Founder and CEO Brett Carlson framed the thesis around ClaimsBridge sitting at the point in the claims workflow where pricing and routing decisions are made. The capital funds product development, platform expansion and further M&A. Alongside the investment, ClaimsBridge acquired DialysisPPO, founded 2006, whose patented program has saved payers over $325 million by capturing Medicare savings on dialysis claims without the usual thirty-month coordination period. (Link)
11. The Difference Card, a Stone Point Capital portfolio company, has acquired healthcare analytics business HealthCorum, expanding its data, provider-scoring and AI navigation capabilities. The Difference Card, the employer health benefits cost-containment platform acquired by Stone Point Capital from Northlane Capital Partners in 2025, has bought HealthCorum. Financial terms were undisclosed. The acquisition adds provider quality scoring across more than 1.5 million providers and over 90 medical subspecialties, folding into the company’s Provider Lookup Manager Tool, plus an AI Navigator supporting natural-language provider search. The strategic logic is margin-relevant: pairing plan-design savings with steerage toward higher-quality, lower-cost providers deepens the value proposition to self-funded employers facing rising trend, and moves the platform from pure cost containment toward navigation. (Link)
12. Beacon Behavioral Partners, based in Louisiana, has partnered with AR Psychiatric and Counseling Center, marking the physician-led behavioral health expansion into Georgia. Beacon Behavioral Partners, a Baton Rouge-headquartered network of independent interventional psychiatric practices, has entered Georgia through a partnership with AR Psychiatric and Counseling Center. Financial terms were undisclosed and both organisations are private. ARPCC operates two locations serving Valdosta, Tifton and South Georgia under co-lead psychiatrists Anil Gupta, MD, and Bhavesh Patel, MD, who retain the physician-led model. SVP of Business Development Todd Mudd positioned the transaction as preserving clinical autonomy while funding growth. Beacon’s model removes operational burden in exchange for scale, and the platform reported more than 250 providers across 45 locations as of its last disclosed count. (Link)
13. Bookmark Medical, a provider-led platform has acquired Village Medical Michigan, including Huron Valley Practice Affiliates,  expanding to Michigan and four other states. Bookmark Medical, the Nashville-based primary care platform rebranded from Village Medical earlier in 2026, closed its Michigan entry effective August 3, 2026. Financial terms were undisclosed and both parties are private. The transaction adds seven primary care practices, a diagnostic center and Huron Valley Practice Affiliates, an independent physician organization, comprising roughly 40 providers, over 350 employees and more than 40,000 patients across Southeast Michigan. CEO Benson Sloan and Chief Physician Executive David Hatfield framed the deal around density and provider support. Bookmark now operates across Arizona, Massachusetts, Michigan and Tennessee, with the physician organization adding affiliated-physician reach beyond owned clinics. (Link)
14. Frazier Healthcare Partners portfolio company LUX Infusion has acquired Infuse IQ, a Cody, Wyoming-headquartered independent infusion therapy provider operating six ambulatory infusion centers. LUX Infusion, the Frazier Healthcare Partners-backed platform formerly known as BioMatrix Specialty Infusion Pharmacy, has added Infuse IQ in its latest tuck-in. Terms were undisclosed. The sponsor’s thesis is site-of-care migration: as payers push infusion out of hospital outpatient departments, LUX is assembling an omnichannel network spanning home infusion and ambulatory centers, now reaching from Alaska to the Southeast. Infuse IQ contributes six clinics serving more than ten specialties with broad payer acceptance and co-pay assistance programs. CEO Brian Zweben cited LUX’s clinician-led model and technology investment as the fit; this follows recent Northeast Infusion Therapy and First Choice deals. (Link)
15. Versant Diagnostics has acquired American Dermatopathology Laboratory, LLC, a dermatopathology practice based in Centerville, Ohio, and welcomed dermatopathologist H. Nicholas Shamma, MD. Versant Diagnostics, a Grapevine, Texas independent physician services company, has acquired Ohio-based American Dermatopathology Laboratory, extending a national roll-up of subspecialty anatomic pathology practices. Financial terms were not disclosed and both parties are private. The Ohio practice folds into Versant DermPath, the company’s dermatopathology-focused entity, with Dr. Shamma joining as an integral partner. CEO Jim Billington positioned the transaction as building one of the country’s strongest dermatopathologist networks and expanding specialist access. The deal follows Versant’s 2025 expansion into Georgia and reflects a consolidation model that pairs digital pathology infrastructure with physician equity participation. (Link)
16. Gastro Health has finalized a partnership with Center for Advanced Gastroenterology, a four-physician Central Florida practice. Gastro Health, a national single-specialty digestive and liver health group, has added Center for Advanced Gastroenterology, which operates offices in Maitland and Lake Nona with four board-certified gastroenterologists and two advanced practice providers. Financial terms were undisclosed and both parties are private. CEO Alan Oliver framed the strategy as extending the network by collaborating with high-quality practices in existing markets, and the platform explicitly characterises the transaction as an acquisition milestone in its growth plan. The eighth Orlando-area deal reflects a density-first consolidation approach that concentrates referral flow and ambulatory endoscopy volume within defined geographies. (Link)
17. Unite Us has acquired Vircho Health, a performance, quality and financial analytics platform for community care networks, strengthening its health and community care infrastructure. Unite Us, the social care coordination network, has acquired Vircho Health including its full team led by co-founders Craig Manson and Evan Jones. Financial terms were undisclosed and both companies are private. The deal responds to a funding shift in social determinants of health, where government payers, health plans and foundations increasingly demand proof of outcomes and quantifiable financial return rather than closed-loop referral confirmation alone. Unite Us brings a thirteen-year dataset of nearly 125 million care connections; Vircho adds dollar-level expenditure tracking and per-organisation performance reporting. Vircho tools already run alongside Unite Us in North Carolina through Impact Health. (Link)
18. Ascend Learning has acquired Teaching Assignment Management System (TAMS), a cloud-based faculty workload platform built at Duke University. Ascend Learning, a healthcare and learning technology company, has acquired TAMS, used by more than 70 institutions including Johns Hopkins, Texas A&M and Marquette. Terms were undisclosed. CEO Lissy Hu framed the rationale as owning the full continuum from faculty planning through student outcomes, building on ATI Nursing Education’s penetration of more than 60% of U.S. nursing schools. The strategic value is cross-sell into an installed base at a moment when nursing programs face faculty shortages and enrolment pressure. Founder David Parrish cited Ascend’s distribution reach as the deal driver; the platform replaces spreadsheet-based assignment and workload processes. (Link)
19. Copley Equity Partners portfolio company FMG Leading has acquired Washington, D.C.-based market intelligence and strategic advisory firm BroadBranch Advisors, adding competitive and customer intelligence capabilities to its healthcare advisory platform. FMG Leading, a Philadelphia-based strategic advisory firm founded in 1984 and backed by Copley Equity Partners since 2022, closed its purchase of BroadBranch Advisors effective July 31, 2026. Terms were undisclosed and both firms are privately held. The sponsor thesis is capability stacking rather than scale: FMG advises investor-backed healthcare executives on growth and value creation, and BroadBranch contributes an “outside-in” competitive and customer intelligence practice, combining market insights with organisational health data on one platform. CEO and Chairman Matt Brubaker cited rising client demand for faster translation of forward-looking intelligence into action. BroadBranch Managing Partner Courtney Matson continues with the combined business. (Link)
20. Tortuga Growth Partners has made a strategic investment in Advanced eClinical Training, an online healthcare certification and workforce development provider, through Tortuga Growth Partners Fund I, L.P. Tortuga Growth Partners, a New York private investment firm built around disciplined buy-and-build, has invested in Advanced eClinical Training out of its debut fund, extending the build-out of its healthcare vertical. Terms were undisclosed. Managing Member Ashray Prasad framed the thesis as backing founders addressing large, enduring problems with structural tailwinds, citing an American Hospital Association projection of a 3.2 million-worker healthcare shortage this year. Senior Managing Director Walt Vester will help scale the platform. Tortuga has assembled a board and advisory group including operating partners Michael O’Neil, who becomes executive chair, Vester and Marty DeMonte alongside co-founders Shay and Shabnam Safarzadeh. (Link)
21. GreyLion and Vestar Capital Partners portfolio company 360training.com, Inc. has acquired select assets of seven San Antonio-based compliance training brands, including American Health Training and National OSHA Foundation. 360training, an Austin-based regulated online training platform owned by GreyLion and Vestar Capital Partners, has executed another add-on in a rapid buy-and-build cadence that already includes ACLS Medical Training, Canadian Food Safety Group and the On The Fly brands in 2026 alone. Terms were undisclosed. The acquired portfolio spans healthcare, OSHA and workplace safety, food handling, forklift operations, hazardous materials, defensive driving and transportation safety, broadening the sponsors’ multi-industry compliance footprint across the United States and Canada. The strategy is consolidation of fragmented, mandatory-certification niches where regulatory complexity supports recurring, non-discretionary demand. (Link)
22. Lee Health has acquired Gardner Orthopedics, a Fort Myers orthopedic practice, expanding the nonprofit system’s musculoskeletal service line across Southwest Florida. Lee Health, a Southwest Florida nonprofit health system, has acquired Gardner Orthopedics, absorbing all 75 employees including five physicians alongside nurses, physical therapists and medical assistants. Financial terms were not disclosed; as a nonprofit system acquisition of a physician practice, no sponsor capital is involved. Kris Fay, Chief Administrative Officer of LPG and Ambulatory Care, positioned the deal as expanding access to orthopedic and musculoskeletal care. The Winkler Avenue facility remains operational, strengthening outpatient footprint. The transaction supports the Lee Health Musculoskeletal Institute build-out at a time of sustained population growth in the region. (Link)
23. Philips International has completed the acquisition of the healthcare consulting, technology and recruiting businesses of The Nash Group, Inc., Advance Solutions International, Inc. and Nursing Advisory Services LLC. Philips International, a Great Neck, New York privately held investment company has closed its purchase of the Nash healthcare businesses. Financial terms were undisclosed. Adrian Miller, Managing Director of Corporate M&A at Philips International, cited the platform’s expertise, longstanding customer relationships and differentiated workforce solutions, and said the buyer will invest in people, technology, business development capability and operating infrastructure. Established in 1992, The Nash Group serves hospitals across staffing optimisation, acuity and workload analysis, operational performance improvement, hospital technology, and domestic and international nurse recruitment. (Link)
24. Codis completes acquisition of Catalent’s Nottingham, UK facility Codis, a global CDMO specializing in spray drying and amorphous solid dispersions, has closed its acquisition of Catalent’s Nottingham, UK facility. The site adds oral solid dose development, clinical supply and small-scale commercial manufacturing capabilities, complementing Codis’ commercial-scale spray drying operations in Haverhill. The combination creates an integrated European pathway from early development through commercial intermediates and finished dose forms. Financial terms were not disclosed. (Link)
25. Nexa Equity portfolio company Facility Grid has acquired PingCx, an autonomous commissioning platform for building automation systems, and launched a unified building lifecycle software platform. Facility Grid, a Waltham, Massachusetts commissioning and operational readiness software provider backed by San Francisco-based growth equity firm Nexa Equity, has acquired PingCx. Terms were undisclosed. Nexa manages more than $1 billion in assets and runs a concentrated investment approach pairing investors with operators. The acquisition converts Facility Grid from a point commissioning tool into a three-product platform, with PingCx becoming FG Validate alongside FG Construct and FG Sustain, the latter launching in September. CEO Daniel Russo positioned the strategy around owning the system of record across a building’s full life rather than only its construction phase. (Link)
26. Sheridan Capital Partners has completed its investment in Carolina Components Group, a Durham, North Carolina supplier of custom-engineered bioprocessing assemblies to biopharmaceutical manufacturers. Sheridan Capital Partners, a healthcare-dedicated private equity firm investing $30 million to $150 million per manufacturing deal out of its $575 million Fund III, has closed a private investment in Carolina Components Group. Financial terms were undisclosed. Partner Michael Bernard described CCG as the output of a multi-year thesis in the pharmaceutical manufacturing supply chain, with the deal led alongside Sean Dempsey and Conor Kolstad. Founder John Cooling and other leaders retain meaningful ownership and Cooling joins the board, while Maurice Phelan, formerly President of Sartorius North America, becomes CEO. CCG serves over 250 biopharma and CDMO customers. (Link)
27. Neuronetics, Inc. (NASD: STIM) and second-largest shareholder Jorey Chernett of Pointillist Family Office have reached an agreement establishing a path to board representation, with largest holder Madryn Asset Management, LP reaffirming its support. Neuronetics (NASDAQ: STIM) has resolved a months-long campaign by Jorey Chernett, whose Pointillist Family Office holds 14.12% of shares outstanding and 10,588,988 shares with sole voting and dispositive power. Chernett had criticised chronic underperformance since the $45 million Greenbrook TMS acquisition in late 2024 and pushed for a sale of the TMS device business; the company is not pursuing that route. Under the understanding, Chernett may recommend a new board appointee and has affirmed comfort with the capital position. Madryn Asset Management Managing Partner Avi Amin, also a director, reaffirmed conviction in the platform. (Link)
28. iSpecimen Inc. (NASD: ISPC) has closed a $5.0 million public offering of common stock and pre-funded warrants, with participating investors subscribing for 996,231 shares and warrants over up to 2,849,923 additional shares. iSpecimen (NASDAQ: ISPC), an online marketplace connecting biospecimen researchers with healthcare specimen providers, priced the offering on August 6 and closed August 7, 2026 for gross proceeds of approximately $5 million. The heavy pre-funded warrant component relative to common stock indicates investors managing beneficial ownership thresholds, a common structure for micro-cap issuers with concentrated demand. Proceeds are earmarked for repayment of outstanding liabilities, potential acquisitions and investments, marketing initiatives, general corporate purposes and working capital. The registration statement was filed June 24, 2026 and declared effective July 30, 2026. (Link)
29. Health Catalyst, Inc. (NASD: HCAT) has completed the sale of its Vitalware mid-revenue-cycle business to Med-Metrix LLC for $147 million in cash and used the proceeds to fully retire its credit facility. Health Catalyst (NASDAQ: HCAT) closed the divestiture of Vitalware to Med-Metrix on July 31, 2026 for $147 million of total cash consideration, subject to customary adjustments. Proceeds plus balance-sheet cash repaid and terminated all obligations under the company’s credit facility, eliminating roughly $19 million of annualised GAAP interest expense based on first-half 2026 figures. The transaction is a balance-sheet reset as much as a portfolio move: management framed the strengthened capital position as funding a narrower roadmap around cost management, clinical quality and consumer loyalty intelligence products. Med-Metrix gains coding compliance, chargemaster, charge capture and price transparency assets. (Link)
30. Solventum Corporation (NYSE: SOLV) has reported second quarter 2026 results and announced plans to separate its Health Information Systems division, following the earlier divestiture of its Purification and Filtration business. Solventum (NYSE: SOLV) posted $2.2 billion of second quarter sales with 9.5% organic growth against 2.2% reported growth, and raised full-year guidance. The capital-structure story is the more investor-relevant one: net debt has fallen $2.6 billion since separation from 3M (NYSE: MMM) to $4.7 billion, funded largely by net proceeds from the September 2025 sale of Purification and Filtration. Management then announced its intention to spin off Health Information Systems, a second act of portfolio separation for a company itself created by spin-off. Shares rose 3.4% after hours to $90.47, surpassing the prior 52-week high. (Link)
31. Care Options for Kids has completed the rebranding of its Chicago-area affiliate Health Force under the Care Options for Kids name, unifying its Illinois pediatric home care identity. Care Options for Kids, a national pediatric home healthcare provider, announced that Health Force has formally transitioned to the Care Options for Kids brand, establishing a single identity in Illinois. No new transaction, consideration or investor was disclosed: Health Force was already part of the platform, making this an integration and branding milestone rather than a fresh acquisition. Operating in the Chicago area since 1993, the business continues providing one-to-one pediatric care at home, in schools and in communities, with local clinicians gaining access to the platform’s shared clinical resources and standardised processes. (Link)

Venture Deals and Other

1. Standard Capital has led a $15 million Series A in San Francisco-based Andromeda Surgical, with participation from Y Combinator, Vox Capital, Lingotto Innovation, Alumni Ventures, WestWave Capital, Pioneer Fund and Phaze Ventures. Standard Capital led the $15 million round for Andromeda Surgical, taking total funding to $30 million as the autonomous surgery company moves from clinical validation to commercial launch. Pioneer Fund has now backed the company twice, starting at seed, and Oman-based Phaze Ventures participates from its earlier investment. Investors are underwriting an endourology-first thesis: the system has performed HoLEP procedures in more than 40 patients across three countries, with enucleation times as fast as 30 minutes against a published average near 90. Andromeda holds clearance in Canada and New Zealand, with first commercial installations expected within two months. (Link)
2. Strategic investors NDS Corporation and Aimed Bio Inc. have backed Inocras Inc.’s oversubscribed $31 million Series B-3 alongside new investors IMM Investment, Korea Investment & Securities, LoftyRock Investment, DT& Investment, Woori Investment & Securities and Shinhan Securities, with existing holders DSC Investment, Dunamu & Partners and InterVest participating. The oversubscribed Series B-3 takes San Diego-based Inocras to approximately $100 million of total funding. The investor syndicate is notably Korea-weighted, reflecting the company’s origins as a KAIST spinout and its installed base across Asia. Capital funds U.S. commercial and operational build-out of its CLIA/CAP-certified whole-genome sequencing and automated bioinformatics infrastructure. Investors are backing demonstrated traction rather than early-stage risk: the platform is used by more than 100 cancer institutions, supports roughly 30 South Korean hospitals and holds meaningful commercial presence in Hong Kong. Strategic participation from Aimed Bio follows a July equity investment and joint research agreement. (Link)
3. UMass Memorial Health has led the $10 million first close of Wellinks’ Series B round, with participation from existing inside investors. UMass Memorial Health, a strategic rather than financial investor, anchored the $10 million first tranche for New Haven-based Wellinks, deepening a multiyear commercial relationship that began with a 2022 UMass Chan research collaboration and a 2024 virtual pulmonary rehabilitation partnership. The investment is underwritten by outcomes data: the joint Healthy at Home study showed participants with more than 60% lower odds of 30-day COPD readmission. Proceeds fund commercial expansion into rural and underserved markets, advance the predictive analytics engine behind the FDA-cleared Spire remote monitoring system, and extend the care model into congestive heart failure. Inside investors supported the round. (Link)
4. Boost VC, Cleo Capital, Manna Ventures and Profluent Capital have backed SkinBit’s $6 million pre-seed round, joined by Lyft, Inc. (NASD: LYFT) co-founder Logan Green and nine board-certified dermatologists. The $6 million pre-seed for Los Angeles-based SkinBit is an unusually well-syndicated first institutional round, pairing four venture funds with an operator angel in Lyft (NASDAQ: LYFT) co-founder Logan Green, who joins the board, and nine practising dermatologists whose participation doubles as clinical distribution. Investors are funding a data-asset thesis rather than a device: proceeds deploy full-body scanners into med spas, longevity clinics and dermatology practices, targeting three locations in 2026 and fifteen by end-2027, with each scan compounding a longitudinal, patient-owned imaging record. Founded 2023 by Jonathan Benassaya, with Stanford and OHSU dermatology leadership attached. (Link)
5. 4DMedical Limited (ASX: 4DX) has made a $3.4 million strategic investment in Seattle-based RevealDx and signed a global distribution agreement for the RevealAI-Lung nodule characterisation software. 4DMedical (ASX: 4DX) is combining a $3.4 million equity investment with exclusive distribution rights across the United States, Europe, Australia and New Zealand, a structure that gives the listed acquirer optionality on RevealDx without full consolidation. The investment follows 4DMedical’s acquisition of Austrian chest CT company contextflow, into whose platform RevealAI-Lung is already integrated and deployed at European clinical sites. The commercial case rests on reimbursement and regulatory position: FDA clearance, European MDR certification, Australian TGA approval and U.S. Medicare coverage under CPT codes 0721T and 0722T, with validation across more than 1,500 patients. (Link)

CLICK HERE to sign up
for all news and updates